$MREO
Mereo BioPharma Group PLC

2024 Q3 Form 10-Q Financial Statement

#000095017024095777 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $0.00 $0.00 $7.128M
YoY Change -100.0%
Cost Of Revenue $0.00 $2.455M
YoY Change -100.0% -797.44%
Gross Profit $0.00 $4.673M
YoY Change -100.0% 1227.56%
Gross Profit Margin 65.56%
Selling, General & Admin $7.868M $9.548M
YoY Change -17.6% 8.01%
% of Gross Profit 204.32%
Research & Development $3.170M $4.946M $7.898M
YoY Change -11.8% -37.38% -40.71%
% of Gross Profit 169.01%
Depreciation & Amortization $100.0K $100.0K $404.0K
YoY Change 0.0% -75.25% -7.34%
% of Gross Profit 8.65%
Operating Expenses $3.170M $4.946M $14.58M
YoY Change -11.8% -66.08% -34.2%
Operating Profit -$9.373M -$12.81M -$9.909M
YoY Change 3.37% 29.32% -54.57%
Interest Expense $353.0K $331.0K -$1.613M
YoY Change -49.57% -120.52% -225.53%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 -$415.0K
YoY Change -100.0% -165.66%
Pretax Income -$15.00M -$12.26M -$11.94M
YoY Change 129.69% 2.66% -39.99%
Income Tax $0.00 $0.00 -$907.0K
% Of Pretax Income
Net Earnings -$15.00M -$12.26M -$11.03M
YoY Change 129.69% 11.11% -42.43%
Net Earnings / Revenue -154.74%
Basic Earnings Per Share -$0.02 -$0.02 $0.00
Diluted Earnings Per Share -$0.02 -$0.02 -$0.02
COMMON SHARES
Basic Shares Outstanding 769.3M 701.4M 628.4M
Diluted Shares Outstanding 770.1M 711.8M 628.4M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $87.43M $42.11M
YoY Change 107.61% -44.89%
Cash & Equivalents $80.50M $87.43M $42.11M
Short-Term Investments
Other Short-Term Assets $4.254M $1.376M
YoY Change 209.16% -49.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $86.72M $93.94M $54.23M
YoY Change 73.23% -33.71%
LONG-TERM ASSETS
Property, Plant & Equipment $315.0K $338.0K $1.565M
YoY Change -78.4% -25.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.023M $2.189M $26.41M
YoY Change -91.71% 0.69%
TOTAL ASSETS
Total Short-Term Assets $86.72M $93.94M $54.23M
Total Long-Term Assets $2.023M $2.189M $26.41M
Total Assets $88.75M $96.13M $80.64M
YoY Change 19.21% -25.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.748M $2.700M $1.911M
YoY Change 41.29% -32.26%
Accrued Expenses $3.529M $3.721M $4.786M
YoY Change -22.25% -5.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.931M $4.674M
YoY Change 5.5% -71.73%
Total Short-Term Liabilities $14.21M $15.47M $17.46M
YoY Change -11.41% -50.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $4.638M
YoY Change -100.0% 218.54%
Other Long-Term Liabilities $568.0K $536.0K $797.0K
YoY Change -32.75% -55.43%
Total Long-Term Liabilities $568.0K $536.0K $5.435M
YoY Change -90.14% 67.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.21M $15.47M $17.46M
Total Long-Term Liabilities $568.0K $536.0K $5.435M
Total Liabilities $16.21M $17.48M $22.89M
YoY Change -23.65% -40.46%
SHAREHOLDERS EQUITY
Retained Earnings -$455.8M -$440.8M
YoY Change
Common Stock $3.051M $3.032M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $72.54M $78.65M $57.75M
YoY Change
Total Liabilities & Shareholders Equity $88.75M $96.13M $80.64M
YoY Change 19.21% -25.36%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$15.00M -$12.26M -$11.03M
YoY Change 129.69% 11.11% -42.43%
Depreciation, Depletion And Amortization $100.0K $100.0K $404.0K
YoY Change 0.0% -75.25% -7.34%
Cash From Operating Activities -$13.26M
YoY Change -29.48%
INVESTING ACTIVITIES
Capital Expenditures $337.0K
YoY Change 3270.0%
Acquisitions
YoY Change
Other Investing Activities $468.0K
YoY Change -52.44%
Cash From Investing Activities $131.0K
YoY Change -86.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.000K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -916.0K
YoY Change 213.7%
NET CHANGE
Cash From Operating Activities -13.26M
Cash From Investing Activities 131.0K
Cash From Financing Activities -916.0K
Net Change In Cash -14.05M
YoY Change -22.5%
FREE CASH FLOW
Cash From Operating Activities -$13.26M
Capital Expenditures $337.0K
Free Cash Flow -$13.60M
YoY Change -27.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 mreo Net Proceeds
NetProceeds
47000000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87400000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001719714
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38452
dei Entity Registrant Name
EntityRegistrantName
MEREO BIOPHARMA GROUP PLC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
One Cavendish Place
dei Entity Address Address Line2
EntityAddressAddressLine2
4th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
London
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
W1G 0QF
dei Entity Address Country
EntityAddressCountry
GB
dei City Area Code
CityAreaCode
+44
dei Local Phone Number
LocalPhoneNumber
333-023-7300
dei Trading Symbol
TradingSymbol
MREO
dei Security12g Title
Security12gTitle
None
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
769262609
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87431000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57421000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4489000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5156000
CY2024Q2 mreo Research And Development Incentives Receivables Current
ResearchAndDevelopmentIncentivesReceivablesCurrent
2020000
CY2023Q4 mreo Research And Development Incentives Receivables Current
ResearchAndDevelopmentIncentivesReceivablesCurrent
1183000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
93940000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
63760000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
338000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
405000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
985000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1245000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
866000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1089000
CY2024Q2 us-gaap Assets
Assets
96129000
CY2023Q4 us-gaap Assets
Assets
66499000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2700000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2346000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3721000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5467000
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4931000
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
679000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
652000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3435000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1021000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15466000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9486000
CY2024Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4394000
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
925000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
412000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
552000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
906000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
536000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
764000
CY2024Q2 us-gaap Liabilities
Liabilities
17479000
CY2023Q4 us-gaap Liabilities
Liabilities
15962000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.003
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.003
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
768821274
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
701217089
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3032000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2775000
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
0
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1230000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
534732000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
486107000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-440836000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-419630000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18278000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17485000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
78650000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
50537000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96129000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66499000
CY2024Q2 us-gaap Revenues
Revenues
0
CY2023Q2 us-gaap Revenues
Revenues
9000000
us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
9000000
CY2024Q2 mreo Cost Of Revenues
CostOfRevenues
0
CY2023Q2 mreo Cost Of Revenues
CostOfRevenues
3430000
mreo Cost Of Revenues
CostOfRevenues
0
mreo Cost Of Revenues
CostOfRevenues
3083000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4946000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3712000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8939000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9019000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7868000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2669000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13777000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9119000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12814000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-811000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22716000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12221000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
559000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
373000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1175000
us-gaap Investment Income Interest
InvestmentIncomeInterest
679000
CY2024Q2 us-gaap Interest Expense
InterestExpense
331000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1029000
us-gaap Interest Expense
InterestExpense
641000
us-gaap Interest Expense
InterestExpense
1829000
CY2024Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-69000
CY2023Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-102000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-517000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
440000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
31000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
-803000
us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
644000
us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
-2010000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
CY2024Q2 mreo Benefit From Research And Development Tax Credit
BenefitFromResearchAndDevelopmentTaxCredit
369000
CY2023Q2 mreo Benefit From Research And Development Tax Credit
BenefitFromResearchAndDevelopmentTaxCredit
621000
mreo Benefit From Research And Development Tax Credit
BenefitFromResearchAndDevelopmentTaxCredit
847000
mreo Benefit From Research And Development Tax Credit
BenefitFromResearchAndDevelopmentTaxCredit
1120000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12255000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1751000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21208000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13827000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12255000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1751000
us-gaap Net Income Loss
NetIncomeLoss
-21208000
us-gaap Net Income Loss
NetIncomeLoss
-13827000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
711770804
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
711770804
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
628421064
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
628421064
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
706407371
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
706407371
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
626185695
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
626185695
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12255000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1751000
us-gaap Net Income Loss
NetIncomeLoss
-21208000
us-gaap Net Income Loss
NetIncomeLoss
-13827000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1400000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-793000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3678000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12250000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-351000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22001000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10149000
us-gaap Net Income Loss
NetIncomeLoss
-21208000
us-gaap Net Income Loss
NetIncomeLoss
-13827000
us-gaap Share Based Compensation
ShareBasedCompensation
4138000
us-gaap Share Based Compensation
ShareBasedCompensation
2576000
us-gaap Depreciation
Depreciation
64000
us-gaap Depreciation
Depreciation
82000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
216000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
171000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
252000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
245000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
517000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-440000
mreo Interest Expenses
InterestExpenses
615000
mreo Interest Expenses
InterestExpenses
941000
mreo Interest Income
InterestIncome
0
mreo Interest Income
InterestIncome
103000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
644000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2010000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-644000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6108000
mreo Increase Decrease In Research And Development Taxes Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxesReceivable
847000
mreo Increase Decrease In Research And Development Taxes Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxesReceivable
1924000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
368000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1494000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
306000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1149000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-316000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-280000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15895000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17002000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
699000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
419000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-699000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-419000
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
0
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
100000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
mreo Consideration Paid For Transaction Cost On Issuance Of Ordinary Shares
ConsiderationPaidForTransactionCostOnIssuanceOfOrdinaryShares
219000
mreo Consideration Paid For Transaction Cost On Issuance Of Ordinary Shares
ConsiderationPaidForTransactionCostOnIssuanceOfOrdinaryShares
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
33000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46781000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
67000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
30187000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-17354000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57421000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68182000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-177000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2139000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87431000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52967000
us-gaap Interest Paid Net
InterestPaidNet
10000
us-gaap Interest Paid Net
InterestPaidNet
863000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
37000
mreo Cash Paid For The Amounts Included In The Measurement Of Operating Lease Liabilities
CashPaidForTheAmountsIncludedInTheMeasurementOfOperatingLeaseLiabilities
387000
mreo Cash Paid For The Amounts Included In The Measurement Of Operating Lease Liabilities
CashPaidForTheAmountsIncludedInTheMeasurementOfOperatingLeaseLiabilities
377000
mreo Issuance Of Common Stock Transaction Costs Not Yet Paid
IssuanceOfCommonStockTransactionCostsNotYetPaid
804000
mreo Issuance Of Common Stock Transaction Costs Not Yet Paid
IssuanceOfCommonStockTransactionCostsNotYetPaid
0
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
50537000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8951000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-798000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2050000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
42838000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12255000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in the Company's unaudited condensed financial statements include, but are not limited to, revenue recognition on contracts with customers and convertible loan notes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p>
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2088000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-2000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47000000
CY2024Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
999000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
78650000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
51402000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12076000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2278000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
1161000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1635000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
44400000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1751000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1400000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
943000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
2000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
4617000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
54000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
49665000
us-gaap Nature Of Operations
NatureOfOperations
<p id="notes_consolidated_financial_statements" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of business</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mereo BioPharma Group plc (the “Company” or “Mereo”) is a United Kingdom (“U.K.”) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (“OI”) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (“AATD-LD”).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is a public limited company incorporated and domiciled in the U.K., and registered in England, with shares publicly traded on the Nasdaq Capital Market via American Depositary Shares (“ADSs”) under the ticker symbol “MREO”. The Company’s registered office is located at Fourth Floor, 1 Cavendish Place, London, W1G 0QF, United Kingdom.</span></p>
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-440800000
CY2024Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
653000
CY2023Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
599000
CY2024Q2 mreo Prepaid Research And Development Services
PrepaidResearchAndDevelopmentServices
1204000
CY2023Q4 mreo Prepaid Research And Development Services
PrepaidResearchAndDevelopmentServices
632000
CY2024Q2 us-gaap Insurance Settlements Receivable
InsuranceSettlementsReceivable
0
CY2023Q4 us-gaap Insurance Settlements Receivable
InsuranceSettlementsReceivable
1950000
CY2024Q2 mreo Employee Taxes On Performance Share Unit Vesting To Be Remitted To Taxing Authorities
EmployeeTaxesOnPerformanceShareUnitVestingToBeRemittedToTaxingAuthorities
1602000
CY2023Q4 mreo Employee Taxes On Performance Share Unit Vesting To Be Remitted To Taxing Authorities
EmployeeTaxesOnPerformanceShareUnitVestingToBeRemittedToTaxingAuthorities
0
CY2024Q2 us-gaap Security Deposit
SecurityDeposit
475000
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
615000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
555000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1360000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4489000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5156000
mreo Amount Received
AmountReceived
1600000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1215000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1205000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
877000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
800000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
338000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
405000
CY2024Q2 us-gaap Depreciation
Depreciation
100000
CY2023Q2 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
100000
CY2024Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
200000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
300000
CY2023Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
200000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
300000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y11M12D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y11M12D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
193000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
191000
us-gaap Operating Lease Payments
OperatingLeasePayments
387000
us-gaap Operating Lease Payments
OperatingLeasePayments
377000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
387000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
771000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
193000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1351000
CY2024Q2 mreo Lessee Operating Lease Liability Undiscounted Adjustment Amount
LesseeOperatingLeaseLiabilityUndiscountedAdjustmentAmount
-120000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1231000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
679000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
552000
CY2024Q2 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
695000
CY2023Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
280000
CY2024Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
1602000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
0
CY2024Q2 mreo Deferred Consideration Liability Current
DeferredConsiderationLiabilityCurrent
276000
CY2023Q4 mreo Deferred Consideration Liability Current
DeferredConsiderationLiabilityCurrent
711000
CY2024Q2 mreo Equity Issuance Costs Payable Current
EquityIssuanceCostsPayableCurrent
804000
CY2023Q4 mreo Equity Issuance Costs Payable Current
EquityIssuanceCostsPayableCurrent
0
CY2024Q2 us-gaap Other Liabilities
OtherLiabilities
58000
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
30000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3435000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1021000
CY2024Q2 mreo Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
765000
CY2023Q4 mreo Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
1821000
CY2024Q2 mreo Accrued Legal Fees
AccruedLegalFees
468000
CY2023Q4 mreo Accrued Legal Fees
AccruedLegalFees
266000
CY2024Q2 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
1120000
CY2023Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
1624000
CY2024Q2 mreo Accrued Audit Fees
AccruedAuditFees
370000
CY2023Q4 mreo Accrued Audit Fees
AccruedAuditFees
671000
CY2024Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
223000
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
338000
CY2024Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0
CY2023Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
382000
CY2024Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
775000
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
365000
CY2024Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
3721000
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
5467000
CY2023Q4 mreo Warrant Liability
WarrantLiability
412000
CY2022Q4 mreo Warrant Liability
WarrantLiability
643000
CY2024Q1 mreo Fair Value Changes During The Year
FairValueChangesDuringTheYear
448000
CY2023Q1 mreo Fair Value Changes During The Year
FairValueChangesDuringTheYear
-542000
CY2024Q1 mreo Warrant Liability Foreign Exchange
WarrantLiabilityForeignExchange
-5000
CY2023Q1 mreo Warrant Liability Foreign Exchange
WarrantLiabilityForeignExchange
4000
CY2024Q1 mreo Warrant Liability
WarrantLiability
855000
CY2023Q1 mreo Warrant Liability
WarrantLiability
105000
CY2024Q2 mreo Fair Value Changes During The Year
FairValueChangesDuringTheYear
69000
CY2023Q2 mreo Fair Value Changes During The Year
FairValueChangesDuringTheYear
102000
CY2024Q2 mreo Warrant Liability Foreign Exchange
WarrantLiabilityForeignExchange
1000
CY2023Q2 mreo Warrant Liability Foreign Exchange
WarrantLiabilityForeignExchange
3000
CY2024Q2 mreo Warrant Liability
WarrantLiability
925000
CY2023Q2 mreo Warrant Liability
WarrantLiability
210000
CY2024Q2 mreo Percentage Of Issued Shares Capital
PercentageOfIssuedSharesCapital
0.003
CY2023Q4 mreo Percentage Of Issued Shares Capital
PercentageOfIssuedSharesCapital
0.004
mreo Disclosure Of Weighted Average Inputs To The Models Used For The Fair Value Of Warrants Granted Explanatory
DisclosureOfWeightedAverageInputsToTheModelsUsedForTheFairValueOfWarrantsGrantedExplanatory
<p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table lists the weighted average inputs to the models used to calculate the fair value of warrants:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.357%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility (%)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate (%)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.05</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.36</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life of warrants (years)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Market price of ADS ($)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.60</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.31</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Model used</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Black-Scholes</span></span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="3" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Black-Scholes</span></span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> </table>
mreo Description Of Expected Volatility Share Options Granted
DescriptionOfExpectedVolatilityShareOptionsGranted
0.95
CY2023 mreo Description Of Expected Volatility Share Options Granted
DescriptionOfExpectedVolatilityShareOptionsGranted
1.02
mreo Description Of Risk Free Interest Rate Share Options Granted
DescriptionOfRiskFreeInterestRateShareOptionsGranted
0.0405
CY2023 mreo Description Of Risk Free Interest Rate Share Options Granted
DescriptionOfRiskFreeInterestRateShareOptionsGranted
0.0336
mreo Expected Life Of Share Options Granted
ExpectedLifeOfShareOptionsGranted
P3Y8M12D
CY2023 mreo Expected Life Of Share Options Granted
ExpectedLifeOfShareOptionsGranted
P5Y2M12D
mreo Market Price Of Ordinary Shares
MarketPriceOfOrdinaryShares
3.6
CY2023 mreo Market Price Of Ordinary Shares
MarketPriceOfOrdinaryShares
2.31
mreo Description Of Option Pricing Model Share Options Granted
DescriptionOfOptionPricingModelShareOptionsGranted
Black-Scholes
CY2023 mreo Description Of Option Pricing Model Share Options Granted
DescriptionOfOptionPricingModelShareOptionsGranted
Black-Scholes
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12531300
us-gaap Revenues
Revenues
0
CY2024Q2 us-gaap Revenues
Revenues
0
CY2024Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2088000
CY2023Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
943000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
4138000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2576000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P1Y8M12D
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12255000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1751000
us-gaap Net Income Loss
NetIncomeLoss
-21208000
us-gaap Net Income Loss
NetIncomeLoss
-13827000
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
711770804
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
711770804
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
628421064
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
628421064
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
706407371
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
706407371
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
626185695
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
626185695
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
0
CY2024Q2 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
0
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
0
CY2023Q2 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
0
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 mreo Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q2 mreo Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-095777-index-headers.html Edgar Link pending
0000950170-24-095777-index.html Edgar Link pending
0000950170-24-095777.txt Edgar Link pending
0000950170-24-095777-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mreo-20240630.htm Edgar Link pending
mreo-20240630.xsd Edgar Link pending
mreo-ex31_1.htm Edgar Link pending
mreo-ex31_2.htm Edgar Link pending
mreo-ex32_1.htm Edgar Link pending
mreo-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
mreo-20240630_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable